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The complement system is an evolutionary old and crucial component of innate 
immunity, which is key to the detection and removal of invading pathogens. It was 
initially discovered as a liver-derived sentinel system circulating in serum, the lymph, 
and interstitial fluids that mediate the opsonization and lytic killing of bacteria, fungi, 
and viruses and the initiation of the general inflammatory responses. Although work 
performed specifically in the last five decades identified complement also as a critical 
instructor of adaptive immunity—indicating that complement’s function is likely broader 
than initially anticipated—the dominant opinion among researchers and clinicians was 
that the key complement functions were in principle defined. However, there is now a 
growing realization that complement activity goes well beyond “classic” immune func-
tions and that this system is also required for normal (neuronal) development and activity 
and general cell and tissue integrity and homeostasis. Furthermore, the recent discovery 
that complement activation is not confined to the extracellular space but occurs within 
cells led to the surprising understanding that complement is involved in the regulation 
of basic processes of the cell, particularly those of metabolic nature—mostly via novel 
crosstalks between complement and intracellular sensor, and effector, pathways that 
had been overlooked because of their spatial separation. These paradigm shifts in the 
field led to a renaissance in complement research and provide new platforms to now 
better understand the molecular pathways underlying the wide-reaching effects of 
complement functions in immunity and beyond. In this review, we will cover the current 
knowledge about complement’s emerging relationship with the cellular metabolism 
machinery with a focus on the functional differences between serum-circulating versus 
intracellularly active complement during normal cell survival and induction of effector 
functions. We will also discuss how taking a closer look into the evolution of key com-
plement components not only made the functional connection between complement 
and metabolism rather “predictable” but how it may also give clues for the discovery of 
additional roles for complement in basic cellular processes.
Keywords: complement, metabolism, evolution, T cells, metabolic disease
2Kolev and Kemper Complement and Metabolic Regulation of Immunity
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 1
iNTRODUCTiON
Detection and subsequent removal or containment of microbes 
and pathogens, harmful entities and altered, dangerous self-
derived antigens by the host’s immune system is key to survival. 
Particularly, the pattern-recognition receptors (PRR) of the 
innate immune system, including for example the toll-like recep-
tors (TLRs), the inflammasomes, and the complement system are 
prime sensors of molecular patterns derived from pathogens or 
otherwise dangerous antigens (pathogen- or danger-associated 
molecular patterns, PAMPs or DAMPs) (1–3). Activation of these 
PPR systems not only induces an immediate strong protective 
effector response by innate immune cells such as neutrophils, 
monocytes, and natural killer T cells but also leads to the activa-
tion and instruction of adaptive immunity (2, 4, 5). Although it 
has long been appreciated that engagement of PPRs on and/or in 
cells and subsequent induction of their respective downstream 
effector pathways is required for the expression and secretion 
of cytokines, growth factors, cytotoxic molecules, and general 
activation of immune cells, what has been unexpected is that 
many of these events are driven by direct impact of PPRs on cell 
metabolism (6). Specifically, the emerging critical role for the 
complement system in the regulation of key metabolic pathways 
of cells has been surprising, as complement is commonly con-
sidered a serum-effective system with its functions mostly fully 
explored.
SYSTeMiC, AUTOCRiNe, AND 
iNTRACeLLULAR COMPLeMeNT iN 
PROTeCTive iMMUNe ReSPONSeS
Systemic- and Serum-Operative 
Complement
The complement system was discovered by Jules Bordet and Paul 
Ehrlich at the end of the nineteenth century as a “system of serum-
circulating proteins complementing antibody-mediated immune 
responses” (7, 8). The complement system that is composed of over 
50 blood- and lymph-circulating, as well as membrane-bound, 
proteins is a central part of innate immunity and constitutes the 
first line of defense in the detection and removal of pathogens 
that have breached the host’s protective barriers. The complement 
proteins circulating in blood are majorly secreted by the liver and 
comprise the PRR components and the effector molecules, which 
exist mostly in inactive pro-forms. The system becomes activated 
in a cascade-like fashion when triggered through one or more of 
the three main activation pathways, the classical, the lectin, or the 
alternative pathway (Figure 1) (9, 10). The generated activation 
fragments then engage membrane-bound complement receptors 
and regulators expressed by cells, which in turn transmit instruc-
tive signals into the cell. Each activation pathway cumulates into 
the generation of the C3 and C5 convertase complexes, which 
cleave C3 into the bioactive opsonin C3b and the anaphylatoxin 
C3a, and C5 into C5b and the anaphylatoxin C5a, respectively. 
Deposition of C5b onto a pathogen surface seeds the generation 
of the pore-forming terminal complement complex (TCC; or 
membrane attack complex, MAC), leading to direct lysis of the 
microbe. Further, the generation of C3b leads to opsonization 
and phagocytic uptake of the targeted pathogen by scavenger 
cells (via engagement of receptors specific for C3 activation 
fragments), while C3a and C5a induce migration and activation 
of innate immune cells and drive a broad inflammatory reaction 
via engagement of their specific G protein-coupled receptors 
(GPCRs) (9, 11, 12). The critical role of serum-circulating 
complement as sentinel for pathogen invasion is underpinned 
by the fact that deficiencies in key complement components 
lead to severe and recurrent infections (13–15). Importantly, 
and similar to TLRs and the inflammasomes, serum-circulating 
complement-derived PRRs recognize not only PAMPs but also 
DAMPs. For example, ficolins and the C1 complex (C1q, C1r, 
and C1s) detect danger molecules produced by stressed and dying 
cells, such as surface blebs on apoptotic cells, and deficiencies or 
dysfunctions in C1 proteins are associated with the autoimmune 
disease systemic lupus erythematosus (SLE) (16, 17). Aside from 
its critical role in innate immune responses, complement also 
impacts heavily on adaptive immunity. Receptors specific for the 
fragments produced by complement activation transmit signals 
into various cells, including B and T cells (18, 19). During B cell 
receptor (BCR) activation, stimulation of complement receptor 2 
(CR2, CD21) through C3d-coated antigen reduces the threshold 
for BCR signaling, thereby providing important costimulation for 
optimal antibody production (20, 21), and explaining why serum 
C3 deficiency often causes common variable immunodeficiency 
(22). Further, complement receptor signaling on B cells and fol-
licular dendritic cells contributes to induction of B cell memory 
and maintenance of B cell tolerance (23, 24), and complement 
receptor activation on T cells is required for the induction of a 
range of effector functions (2, 11, 25, 26).
Autocrine- and intracellular-Operative 
Complement
Traditionally, the observed effects of complement receptor activa-
tion on various cell types was thought to be mediated solely by 
complement activation fragments generated in serum, the lymph, 
or interstitial fluids. However, particular work on the effects of 
complement on T cell responses demonstrated that comple-
ment activation fragments generated by antigen-presenting cells 
(APCs) and T cells themselves function in an autocrine and also 
unexpectedly in an intracellular fashion and are required for 
normal T cell immunity (27–31) (Figures 2A,B). For example, 
in resting human CD4+ T cells, activation of C3 occurs continu-
ously within the cell through cleavage via the protease cathepsin L 
(CTSL) into bioactive fragments C3a and C3b. C3a generated by 
this “pathway” activates the C3aR located on lysosomes, and this 
process is required for homeostatic survival of T cells (Figure 2A) 
(31). T cell receptor (TCR) activation induces the rapid trans-
location of intracellular C3a and C3b to the cell surface where 
they engage surface C3aR and the costimulatory complement 
receptor/regulator CD46 (membrane cofactor protein, MCP), 
respectively, two events vitally required for interferon (IFN)-γ 
production and human T helper cell type 1 (Th1) induction (of 
note, serum-derived C3 cannot drive this response) (Figure 2B). 
Indeed, individuals lacking CD46 expression or C3 secretion by 
FiGURe 1 | Systemic complement activation. Serum-circulating complement can be activated via three pathways: the classical, lectin, and alternative pathways, 
which all cumulate in the formation of multiprotein complexes termed C3 convertases. The classical and lectin pathway C3 convertases (C4bC2a) and the alternative 
pathway C3 convertase (C3bBb) lead to cleavage of C3 into the opsonin C3b and the anaphylatoxin C3a. Properdin (P) is a stabilizator of the alternative C3 
convertase. Upon subsequent generation of C5 convertase (C4bC2aC3b for the classical and lectin pathways, C3bBbC3b for the alternative pathway), C5b and the 
anaphylatoxin C5a are produced, with surface-bound C5b initiating the formation and insertion of the terminal complement pathway (TTC; or membrane attack 
complex, MAC) on pathogens (or other target membranes).
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T cells have diminished Th1 immunity (but normal Th2 responses) 
and suffer from recurrent infections (32, 33). Conversely, 
uncontrolled intracellular C3 activation leads to dysregulation of 
CD46-mediated stimulation of human T cells and contributes to 
pathologically hyperactive Th1 responses in rheumatoid arthritis 
(RA) (33). Human CD4+ T cells also contain an intracellular C5 
activation system, and the engagement of the intracellular C5a 
receptor C5aR1 (CD88) upon TCR stimulation is required for 
normal production of reactive oxygen species (ROS) and NLRP3 
inflammasome-driven intrinsic IL-1β secretion that supports 
optimal and sustained Th1 induction during T cell migration into 
tissues (Figure 2B) (34). In mice [which do not express CD46 
on somatic tissue (35)], activation of the anaphylatoxin receptors 
C3aR and C5aR1 expressed by T cells is also critical for induction 
of normal Th1 and Th17 activity, and also controls natural regula-
tory T (Treg) cell responses (30, 36, 37). T cells from mice defi-
cient in the C3ar and C5ar1 additionally show reduced survival in 
the periphery, further substantiating a role for these receptors in 
T cell homeostasis (30). Of note though, in the studies conducted 
on mouse T cells so far, a functional role for intracellular comple-
ment activation had not yet been addressed.
Autocrine-active complement is also needed for normal Th1 
cell contraction (Figure 2B): after successful CD46-driven Th1 
expansion, CD46 engages in an as yet undefined crosstalk with 
the IL-2 receptor and induces IL-10 co-production in Th1 cells 
that “switches” these cells into a (self)regulative contraction 
phase (33). Deviations in this crosstalk prevent normal IL-10 
co-induction and contraction in Th1 cells and contribute to 
chronic disease settings, including multiple sclerosis (MS) (38) 
and RA (33). Further, autocrine surface engagement of the 
alternative C5aR2 (also known as C5L2 or GPR77) via intracel-
lularly generated and then surface-shuttled C5a/C5a-desArg 
negatively regulates intracellular C5aR1 stimulation and, thus, 
also aids in Th1 contraction (Figure 2B). Although the biologic 
role of intracellular complement activation is currently best 
studied in human CD4+ T cells, it has been observed in all cells 
analyzed for far and is therefore likely of broad physiological 
relevance (31).
Thus, complement activation takes place at different loca-
tions and it is the location that dictates function: while serum-
circulating complement is critical for its sentinel function in the 
recognition and removal of pathogens breaching host barriers, 
autocrine-functioning complement directs adaptive T cell and 
APC responses and tonically active intracellular complement 
may sustain cell homeostasis. Particularly, the latter concept 
aligns well with the growing appreciation that complement plays 
an unanticipated active role in tissue development, homeostasis, 
and repair. Although the function of intracellular complement 
and its connection with cell metabolism has not yet been 
investigated during tissue maintenance, complement-mediated 
signals are crucial for liver and retina regeneration after injury 
and for bone healing (39–42). For recent reviews into these 
unexpected “anti-inflammatory” complement activities, please 
see Ref. (2, 11, 43).
FiGURe 2 | Autocrine and intracellular complement activation. (A) In resting T cells, C3 is processed intracellularly by the protease cathepsin L to generate 
bioactive C3a that sustains low-level mechanistic target of rapamycin (mTOR) activity via the engagement of the intracellular C3aR expressed on lysosomes and 
thus contributes to homeostatic survival of CD4+ T cells. (B) Local complement activation is triggered when activating signals [here, T cell receptor stimulation or 
toll-like receptors activation on antigen-presenting cells (not shown)] initiate secretion of preformed C3, C5, factor B, and factor D located in cellular storages, 
leading to C3 and C5 convertase formation in the extracellular space as well as on the cell surface—and the generation of C3a, C3b, C5b, and C5a (1). These 
complement fragments bind to their respective receptors on the T cell surface and induce Th1 induction with interferon (IFN)-γ secretion. C5 is also processed 
intracellularly by a yet unknown protease/convertase into C5a and C5b, and this process is increased through CD46-mediated signals. Intracellular C5a engages the 
intracellular C5aR1, which triggers NLRP3 inflammasome assembly and intrinsic IL-1β secretion that sustains Th1 induction in an autocrine fashion (2). Importantly, 
autocrine CD46 activation in conjunction with IL-2R signaling also induces IL-10 co-production in Th1 cells and the transition into a (self)regulative Th1 contraction 
phase (3). This “IL-10 switch” is accompanied by autocrine surface engagement of the C5aR2 via surface-shuttled C5a/C5a-desArg (3) through an as yet undefined 
signaling pathway (but possibly through direct suppression of intracellular C5aR1 activity, not shown).
4
Kolev and Kemper Complement and Metabolic Regulation of Immunity
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 1
COMPLeMeNT AND MeTABOLiSM
The discovery of an intracellular complement system, the com-
plosome, further substantiates the growing notion in the field 
that complement may not serve strictly classic immune-related 
functions but that this system may also control basic processes of 
the cell and particularly those of metabolic nature. Such a general 
and driving role for complement in cell metabolism could also 
explain its impressive and seemingly ever expanding range of 
effector functions.
Systemic and extracellular Complement in 
Metabolism
The idea that complement may aid in basic cellular processes is 
not new. In fact, a functional connection between complement 
activity in serum and regulation of lipid metabolism has already 
been made very early on, in the late 1980s when the desargin-
ated form of C3a, C3a-desArg [initially identified as acylation 
stimulation protein (ASP)], was shown to stimulate triglyceride 
(TG) accumulation and glucose transport in adipocytes through 
interaction of C3a-desArg with the C5aR2 (44). Although C5a 
and C5a-desArg, verified binding partners to C5aR2, seem to 
play a subordinate role in these processes (45), recent data sug-
gest that C3a-desArg is unable to bind C5aR2 (46) and hence 
the mechanism by which C3a-desArg mediates TG regulation 
operates highly likely rather through C3aR signaling. Generation 
of metabolism-modulating C3a-desArg is mostly dependent on 
alternative pathway activation because both C3-deficient and 
factor B (FB)-deficient mice exhibit decreased glucose toler-
ance and delayed clearance of TG and non-esterified fatty acids 
when compared with wild-type mice (47). Plasma levels of C3a-
desArg are also increased in obese individuals and in patients 
suffering from diabetes type II (11, 48). However, increased or 
uncontrolled activation of the classical complement pathway 
also contributes to dysregulated TG clearance as C1q binding to 
adiponectin was observed in obesity and could further augment 
C3a-desArg levels via increased local complement activation 
and serum carboxypeptidase N-mediated processing of C3a into 
C3a-desArg (49) (Figure  3). This aligns with the finding that 
heightened complement activation indeed correlates with the 
induction of insulin resistance, a cardinal “feature” of severe obe-
sity (50). C1q-deficient mice fed with a high-fat diet accumulated 
FiGURe 3 | The role of systemic complement in metabolism. Metabolically active proteins can activate systemic complement in the absence of infection. For 
example, adiponectin activates directly C1q, which results in the generation of C3a and C5a fragments via classical pathway activation. The anaphylatoxins are 
further processed by carboxypeptidase N (CPN) to C3a-desArg and C5a-desArg, which then impact on triglyceride (TG) clearance, increase insulin resistance, and 
alter adiposity by affecting signaling through the three anaphylatoxin receptors C3aR, C5aR1, and C5aR2 in several cell types such as adipocytes and pancreatic 
β-cells via diffusion into respective tissues. Importantly, although not yet formally proven, locally generated and activated complement also likely affects adipocytes 
activity as these cells are a major source of Factor D and can also synthesize and secrete other complement proteins such as Factor B, C3, and C5. These proteins, 
when secreted, form extracellular C3 and C5 convertases and generate locally C3a and C5a fragments, which engage their respective receptors and trigger AKT 
and NF-κB signaling that contributes to adipocyte development and activity.
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lower levels of complement activation products in their livers and 
were protected from hepatic insulin resistance (51), while CD55 
(decay acceleration factor, DAF)-deficient animals, which lack a 
key negative complement regulator and have therefore increased 
complement C3 and C5 activation, were more sensitive to the 
development of insulin resistance and also showed altered lipid 
handling and increased adiposity (52). Interestingly though, mice 
deficient for the only positive complement regulator, properdin, 
display also increased fat storage upon a high-fat diet and this is 
associated with decreased energy expenditure and delayed TG 
clearance but with no changes in glucose uptake (53). Thus, today 
we acknowledge that complement plays an important role in 
metabolic organs and tissues such as pancreas, liver, and adipose 
tissue (54). Furthermore, and similar to the role of intracellular 
C3a in the homeostatic survival of T cells (see above), controlled, 
tonic levels of complement activation may contribute to the nor-
mal function of these tissues as C3a, C3a-desArg, and C5a via 
all three anaphylatoxin receptors direct adipocyte development 
(45) and energy regulation (55–57) as well as control of insulin 
secretion by pancreatic β-beta cells (11, 54) (Figure 3). And also 
in analogy to what is observed in immune cells, when comple-
ment is activated either above or below threshold levels, also cells 
constituting metabolic tissues can acquire a pathological hypo- or 
hyperactive phenotype, which may sustain or exacerbate meta-
bolic pathology via a detrimental feedback loop.
The contributions of systemic liver-derived versus local 
complement activation in metabolic disease have rarely been 
addressed in published studies; however, it is clear that not all 
effects observed are solely due to systemic complement activity. 
For example, specifically, adipocytes produce several complement 
proteins, including FB, factor D (FD, also known as “adipsin”), 
factor H (FH), C3, C1q, and properdin (53) and dysregulated 
synthesis of these factors by adipocytes is associated with partial 
lipodystrophy and loss of subcutaneous adipose tissue of the 
upper body (58). Therefore, unwanted increased local generation 
of a range of key complement factors by enlarged adipose tissue 
6Kolev and Kemper Complement and Metabolic Regulation of Immunity
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(Figure 3) could clearly contribute to a dysbalance in autocrine 
complement activity (on adipocytes and also subsequently on 
incoming immune cells) with damaging effects on the environ-
mental metabolic milieu (49).
For an excellent in-depth overview on the role of systemic 
complement in metabolic disease, please see Ref. (54).
intracellular and Autocrine Complement in 
Metabolism
Similar to the work on the vital role of autocrine-functioning 
complement in the induction and contraction of human and 
mouse effector T cell responses, the discovery of the complosome 
also allowed us to better understand how tightly complement and 
cell metabolism are interlinked.
Research on the functional cross-connection between 
immune cell activation, the induction of effector function, and 
cell metabolism is currently among the “hottest” fields in immu-
nological research—and it is now broadly acknowledged that 
polarized differentiation of immune cells, triggered by stimula-
tion with distinct activation, stress, and/or danger signals, drives 
cell-specific remodeling of metabolic pathways. Importantly, 
distinct metabolic signatures encompassing metabolic enzymes, 
nutrient sensor and metabolic checkpoint systems, and epige-
netic changes in genes coding for proteins involved in metabolic 
pathways “accompany” distinct phases of immune responses 
including the non-activated and/or resting state, the adaption 
response, and the contraction and memory phases (6, 59, 60). 
Because T cell development and the respective activation states 
of T cells (naïve, effector, and memory) can be manipulated 
and monitored relatively easily in  vitro and in  vivo, significant 
progress has been made particularly in understanding how the 
cell metabolic machinery enables and drives T cell immunity 
(61). Quiescent T cells generally maintain a status of low 
glycolytic activity and reduced nutrient intake, using oxidative 
phosphorylation (OXPHOS) as “tonic survival” energy source, 
while activated cells increase both glycolysis and OXPHOS as 
well as nutrient influx and, upon contraction, reduce levels of 
glycolysis and return to a state of low-level OXPHOS (59). More 
specifically, in T cells, cognate antigen and costimulation of 
metabolically quiescent naïve and memory CD4+ and CD8+ T 
cells together with specific environmental signals (for example, 
cytokines) induces proliferation and differentiation into distinct 
effector populations (helper CD4+ T cell subsets Th1, Th2, Th17, 
Treg cells, and CD8+ cytotoxic T cells, respectively) (59, 62, 63). 
T cell differentiation into effector cells initiates dramatic changes 
in cellular metabolic pathway usage. A key event during meta-
bolic remodeling in activated T cells is the upregulation of aerobic 
glycolysis (Warburg effect), which is a prerequisite for growth and 
expansion and acquisition of effector function (64, 65). Glycolytic 
metabolites and intermediary pathways that stem from glycolysis 
are essential for biomolecular synthesis in proliferating cells (64). 
Activation of T cells also enhances mitochondrial biogenesis, 
uptake of amino acids (AAs), and glutaminolysis (66, 67). The 
metabolic checkpoint kinase mechanistic target of rapamycin 
(mTOR) senses and integrates incoming signals, particularly AA 
availability, to regulate metabolic adaptation in cells. Activation 
and lysosomal translocation of mTOR subsequently triggers 
glycolysis [via induction of hypoxia-inducible factor 1α (HIF-
1α) that controls the expression of key glycolitic enzymes (68)], 
OXPHOS, and lipid synthesis toward threshold levels needed for 
proliferation and differentiation of resting T cells into effector 
cells (69–71). While the underlying reasons for this are not fully 
understood, it seems that the production of the key inflammatory 
cytokine IFN-γ (thus, Th1 induction) poses an exceptionally high 
glycolytic demand on T cells (65, 72).
Although this notion was not the focus of those studies, ear-
lier work on the role of autocrine anaphylatoxin activity during 
mouse CD4+ and CD8+ T cell activation nonetheless suggested 
already the direct impact of complement on cell metabolism: 
autocrine engagement of the C3aR and C5aR1 on T cells activate 
the phosphatidylinositol-4,5-bisphosphate 3-kinase PI(3)K and 
protein kinase B (PKB, also known as AKT) signaling cascades 
to promote CD4+ and CD8+ T cell activation, proliferation, and 
survival (29, 30). Consequently, circulating T cells from C5ar1−/− 
mice have a decreased lifespan (30). However, T cells from these 
mice were also unable to produce normal amounts of IFN-γ 
and to generate optimal Th1 responses (30, 73). In retrospect, 
this “combined” phenotype is unsurprising, given that PI(3)K 
and AKT are key upstream activators of mTOR (74, 75) and that 
the PI(3)K–AKT–mTOR axis is fundamental to the activation of 
glycolysis and anabolic pathways as well as the regulation of cell 
survival via induction of the antiapoptotic B-cell lymphoma 2 
protein (BCL2) (76).
The novel role of the complosome in the direct regulation of 
cellular nutrient influx and sensing (see below) aligns well with 
the increasing realization that—although initially discovered as 
pathogen sensors—the ability of the TLRs, the inflammasomes, 
and complement to recognize an imbalance in normal cell 
metabolic processes and to help directing reactive responses is 
of equal importance to the maintenance of cell homeostasis (77, 
78). Moreover, normal regulation of cell metabolism by these old 
systems requires their coordinated functional crosstalk (77). For 
example, TLR-dependent sensing of the low-level inflammation 
accompanying a sustained high-fat diet and obesity controls the 
resistance to insulin (79, 80) and possibly glucose metabolism 
in neurons (77, 81). Further, metabolites generated during cell 
proliferation and effector activity (such as high glucose and AA 
influx and adenosine triphosphate and ROS generation) induce 
the NLRP3 inflammasome, while metabolites connected with 
quiescent, contracting, or tolerogenic cell responses inhibit the 
inflammasome activities (82, 83).
While cell metabolic changes regulate NLRP3 activation and 
inhibition, it seems that at least in human T cells, complement 
activation is rather upstream of cell metabolism and a driving 
force behind sustaining metabolic homeostasis in resting cells 
as well as mediating nutrient transport during cell activation. 
For example, the intracellular C3a generated by CTSL-mediated 
cleavage of C3 within resting T cells drives C3aR signaling on 
lysosomes and via this low level of mTOR activity needed for T 
cell survival (31) (Figure 2A). Interestingly, this work on intracel-
lular C3 activity led also to the discovery that T (and other) cells 
from patients with serum C3 deficiency produce normal amounts 
of intracellular C3a from mutated C3 protein to ensure cell 
FiGURe 4 | Autocrine and intracellular complement drives key T cell metabolic pathways during T helper cell type 1 induction. T cell receptor and 
CD28-driven autocrine engagement of CD46 CYT-1 (by C3b) leads to upregulation of genes coding for the glucose transporter GLUT (SLC2A1), and the amino acid 
channel LAT1 (SLC7A5), allowing for increased influx of glucose and amino acids (AA) into the cell (2). In parallel, CD46 CYT-1-mediated signals induce increased 
expression of LAMTOR5, and via this assembly of the lysosome-based machinery enabling AA sensing via mTOR complex 1 (mTORC1), which then leads the 
induction of glycolysis and OXPHOS required for interferon (IFN)-γ production. Surface activation of the C3aR by C3a activates PI3K and AKT and further sustains 
mechanistic target of rapamycin (mTOR) activity. Intracellular C5aR1 stimulation (at a not yet defined cellular compartment) drives mitochondrial reactive oxygen 
species (ROS) production, which induces NLRP3 inflammasome activation and maintenance of IFN-γ secretion during T cell migration into the (inflamed) tissues.
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survival but that any C3 activation fragments fail to be secreted 
(31). TCR stimulation of “healthy” CD4+ T cells engages CD46 
costimulation via surface-shuttled C3b, an event that is critically 
required for increased expression of the glucose transporter 
GLUT1 (SLC2A1), and the AA transporter LAT1 (SLC7A5), 
that both allow for the heightened influx of “food” in the form of 
glucose and AAs fueling T cell activation and particularly IFN-γ 
production (28) (Figure  4). In addition to active regulation of 
nutrient transport, CD46 also partakes in subsequent intracel-
lular nutrient sensing. CD46-mediated signals were also required 
for the expression of the late endosomal–lysosomal adaptor, 
MAPK and MTOR activator 5 (LAMTOR5), a recently described 
component of the Ragulator complex, which is essential for AA 
sensing by mTOR complex 1 (mTORC1). In consequence, T cells 
from CD46-deficient (and serum C3-deficient) patients failed to 
upregulate GLUT1, LAT1, and LAMTOR5 upon activation and 
showed diminished mTORC1 activity and IFN-γ production (28, 
84) (Figure 4). Conversely, uncontrolled intracellular C3 activa-
tion by CSTL and thus hyperactive CD46 signaling occurs in T 
cells isolated from the inflamed joints of patients with juvenile 
idiopathic arthritis and underlies exaggerated mTOR activity and 
IFN-γ secretion in T cells isolated from these patients (31).
Recent work from our group demonstrated that T cells also har-
bor an intracellular C5 activation system and that signals driven 
by the intracellularly expressed C5aR1 are required to induce the 
high(er) levels of oxygen metabolism that sustain particularly Th1 
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responses after induction (34) as augmented intracellular C5a 
generation from C5 stores (via a yet undefined mechanism) upon 
TCR and CD46 costimulation induces mitochondrial production 
of ROS. While CD46 activation simultaneously increases NLRP3 
and IL1B gene transcription, the heightened levels of ROS func-
tion as a required signal for NLRP3 inflammasome activation 
and assembly that culminate in the activation of capsase-1 and 
secretion of bioactive IL-1β (34) (Figures 3 and 4). IL-1β gener-
ated by Th1 cells was not required for IFN-γ induction per se but 
needed to sustain optimal levels of IFN-γ during the “dislodge” 
of T cells from APCs after priming and their migration back into 
(inflamed) tissues. Thus, Nlrp3−/− CD4+ T cells (in otherwise 
Nlrp3-sufficient animals) produce only about 50% of IFN-γ upon 
activation, and this leads to uncontrolled expansion of Th17 cells 
in the mouse intestine in a T cell transfer model of colitis (34). 
Interestingly, intracellular and autocrine activity of complement 
within CD4+ T cells is not required for successful Th2 immunity 
as C3- and CD46-deficient patients mount normal Th2 responses 
(28, 84). Similarly, only complete absence of CD46-mediated sig-
nals reduce IL-17 secretion while a reduction in CD46 expression 
levels on T cells leads to a proportional reduction in IFN-γ secre-
tion (28). Furthermore, the intracellular C5aR1-induced ROS 
production drives specifically IFN-γ secretion as suppression of 
C5aR1 activity or ROS generation fails to affect Th2 cytokine pro-
duction (34). The reasons for this particularly “intimate” connec-
tion between complement and metabolically demanding IFN-γ 
production are currently unclear but could possibly be rooted in 
the early co-evolution between complement and metabolism (see 
Early Coevolution of Complement and Metabolism). The emerg-
ing concept that the “complosome” (9), in direct crosstalk with 
other intracellular effector systems, emerges as critical regulator 
of normal cell physiology fits indeed well into the scheme that 
these old immune sensor systems may serve additional and 
yet to be discovered functions at novel locations: for example, 
two recent studies describe an unexpected role for the NLRP3 
protein in the nucleus—as transcription factor (TF) regulating 
Gata3 gene expression in mouse CD4+ T cells (85)—and for the 
secreted NLRP3 inflammasome as extracellular danger signal 
that amplifies the inflammatory response of macrophages (86).
Importantly, distinct CD46-mediated signals also actively 
contribute to the metabolic changes that drive Th1 contraction. 
After successful induction of IFN-γ secretion and Th1 effec-
tor function, CD46-mediated signals together with—not yet 
understood—incoming signals from the IL-2R also induce 
the switch from a high glycolytic state back to steady-state gly-
colysis levels in CD4+ T cells and, via this, subsequently IL-10 
co-production and finally Th1 contraction (28, 33). It should 
be noted that successful CD46-driven IL-10 induction and Th1 
contraction also requires a simultaneous decrease in intracel-
lular C5aR1 signaling mediated through autocrine surface 
C5aR2 engagement as high levels of intrinsic IL-1β production 
inhibit IL-10 switching (34). This is exemplified by our observa-
tion that CD4+ T cells from patients with cryopyrin-associated 
periodic syndrome (CAPS) that have constitutively active 
NLRP3 due to mutations in the NLRP3 gene have increased 
intrinsic IL-1β production and hyperactive Th1 responses that are 
unable to switch into normal IL-10 co-production (34). While the 
signaling pathways that mediate the autocrine and intracellular 
anaphylatoxin receptor functions during Th1 effector responses 
are ill defined, we know more about the molecular mechanisms 
by which CD46 regulates cell metabolism. CD46 is expressed in 
distinct isoforms (due to differential splicing of a single gene) 
in CD4+ T cells and these isoforms differ in the expression of 
their cytoplasmic domains, termed CYT-1 and CYT-2. Both 
tails transduce intracellular signals in a range of cell populations 
(28, 87). Non-activated CD4+ T cells express predominantly 
CD46-CYT-2 (31) while TCR activation leads to the upregulation 
of the CYT-1-bearing CD46 isoform. And it is CYT-1 that drives 
the expression of GLUT1, LAT1, and LAMTOR5—all required 
for mTORC1 assembly and activation with subsequent increased 
glycolysis, OXPHOS, and IFN-γ secretion (28, 88). The switch 
from high to low glycolysis and OXPHOS, on the other hand, 
is mediated by CD46 isoforms expressing CYT-2, which again 
become the predominant CD46 isoforms in contracting T cells 
(28, 31). Moreover, the intracellular tails of CD46 are processed by 
γ-secretase (88), and we demonstrated that nuclear translocation 
of both domains occurs and that particularly translocation of 
CYT-1 into the nucleus is required for Th1 induction (28). These 
observations make it a possibility that CD46 intracellular domains 
may interact with and modulate the function of TF complexes 
(possibly as activators and/or inhibitors) and via this directly 
control metabolic pathways. Importantly, CD46 expression in 
rodents is confined to non-somatic tissues (89) and a comple-
ment receptor/regulator or alternative receptor serving as the 
murine homolog of CD46 in regard to regulation of metabolic 
programing during Th1 induction and regulation has so far not 
been identified. Thus, there are substantial differences in the 
complement-mediated signaling pathways regulating adaptive 
immunity between species, and this currently poses a hurdle in 
the straightforward further exploration of CD46’s in vivo role in 
cell metabolism.
In the above sections, we have focused on the direct impact 
of autocrine and intracellular complement on key metabolic 
pathways and particularly on T cells as this new functional 
complosome–metabolism axis has so far best been described 
in this cell type. However, complement-mediated regulation 
on metabolism likely occurs in a wide range of cells, clearly 
engages other (intracellular) effector systems, and impacts on 
additional cell basic physiological pathways such as cell survival 
and autophagy. We refer the readers to two recent reviews that 
cover these important additional subjects in-depth including an 
outlook into potential novel roles for complement in infection 
and in diseases with a metabolic “angle” (6, 82).
CURReNT SUBSTANTiAL CHANGeS iN 
OUR PeRSPeCTiveS ON THe 
COMPLeMeNT SYSTeM
The first part of this review summarized published recent 
developments in the complement field that allow to argue that 
complement plays unexpectedly vital roles in single cell and 
organism-wide metabolism. In conjunction with the discover-
ies of new sites of action (intracellularly) and strong indication 
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that complement also partakes in general basic cell physiology, 
our perception of this ancient immune surveillance system 
is now changing. Complement was initially discovered as a 
serum-active system and was ever since known as the first line 
of defense against pathogen- and self-derived dangers detected 
in blood and other body fluids (10, 90). However, the existence 
of a complosome and its direct ability to regulate cell metabolism 
suggests that complement may have functioned originally as an 
intracellular sensor system and only became a secreted and “sys-
temic” system when life evolved from single cell to multicell and 
then to multitissue/organ organisms. Thus, complement may have 
moved from regulating intracellular physiological (nutrient) bal-
ance and cell survival early on towards directing cell autonomous 
immunity via induction of effector function after cell activation 
and finally into the prime guardian of the extracellular space as 
we know it today. This view finds support in the recent observa-
tions that other classic key immune mediators such as cytokines 
and the inflammasomes also support very basic cell activities. 
For example, several cytokines emerged during evolution well 
before their respective receptors and can directly act as TFs in 
the nucleus (91). Similarly, the NLRP3 protein also has TF activity 
and orchestrates the induction of Th2 responses in mouse CD4+ 
T cells via directly initiating Gata3 gene expression (85). And as 
mentioned above, γ-secretase-mediated cleavage of the intracel-
lular domains of CD46 allows for the nuclear translocation of 
CYT-1 and CYT-2 where these domains likely directly modulate 
the activity of TF complexes (28). The early evolutionary appear-
ance of PRRs (see below), their extensive involvement in normal 
cell physiology, and the strong association with inflammatory 
and/or metabolic disease states upon dysregulation of these 
innate immune components (54, 92, 93) lends further argument 
to the growing understanding that PRRs may not have evolved 
primarily to protect against infection, but rather as sensors of 
metabolic changes or imbalances (94). Thus, the second part 
of this review will now take on a more “perspective-like” focus 
and explore certain aspects of complement that may support its 
potential functional origin and emergence from within the cell.
eARLY COevOLUTiON OF COMPLeMeNT 
AND MeTABOLiSM
Metabolic activity is the defining characteristic of life. Metabolism 
evolved from initial oxidation of inorganic matter and CO2 in 
chemoautotrophic organisms about 3.8–2.5 billion years ago 
to usage of the glycolysis pathways in organisms—probably 
around 2.4–1.6 billion years ago—and finally to the emergence 
of OXPHOS around 1.85 billion years ago (95). Glycolysis as 
means to generate energy is central to almost all known living 
organisms. However, it was the requisition of mitochondria by 
cells, and with this, the acquisition of OXPHOS in the presence 
of an atmosphere increasingly rich in oxygen that was the crucial 
step in metabolic evolution as this process provided the platform 
for sufficient energy generation to sustain complex multicellular 
life (96, 97). Interestingly, the TLRs and the NOD-like receptors 
appeared when the first primitive multicell layer animals, marine 
sponges (Demospongiae: Porifera), evolved. Porifera are classified 
as Metazoa and are considered “precursors” to modern complex 
animals, which belong to the Eumetazoa clade (Figure 5A) (98). 
Sponges are filter feeders and have no circulatory systems or 
organs and are classified as Parazoa (a subkingdom of animals). 
Similarly, key components of the complement system represent-
ing mostly the alternative pathway also appear very early in 
Cnidaria (Eumetazoa, also see Figure 5A) at the same time as 
Porifera evolved (32, 99) with C3 (and other thioester-containing 
proteins (TEPs), see below) and FB already present in sea anemo-
nes (100, 101). Subsequent studies on the evolution of the distinct 
complement components further solidified their early emergence 
and demonstrated that the complement protein families C3/
C4/C5, Bf/C2, C1q/MBL/ficolin, MASP/C1rs, and the TCC/
MAC evolved through duplications of core complement genes 
appearing already in primitive species (102). For example, the 
genes coding for C4 and C5 arose from multiplication of the C3 
gene once in the Urochordates and once in the vertebrates before 
the emergence of cartilaginous fish (103, 104), while a precursor 
Bf/C2 gene appeared before the divergence of Cnidaria and 
Bilateria (99). The PPR MBL together with MASP1 and 3 are 
present in the most primitive jawless vertebrates (Agnatha), while 
this phylogenetic group lacks components of the classical path-
way C1q/C1r and C1s (32, 105–107) (Figure 5B). Interestingly, 
TCC/MAC assembly with fully functional lytic activity seems to 
also have evolved only later in the higher jawed vertebrate lineage 
(104, 108). Similarly, effective regulators of complement activa-
tion and receptors for complement activation fragments have 
so far only conclusively been described in bony fish and higher 
vertebrates (108). However, paired CD18 and CD11 (CR3-like) 
homologs are present in several Urochordate species and medi-
ate recognition of complement-opsonized antigens (109), while 
leukocytes of some Agnatha respond to anaphylatoxins—but 
with the responsible receptors remaining to be identified (110).
Thus, core pathways regulating cell metabolism and 
 complement—or PRRs in general—“met” early in evolution 
(possibly triggered by the appearance of multicellularity) and 
it further seems that complement was initially opsonic (and/or 
metabolic, see below) and only later in evolution became involved 
in the direct lysis of pathogens.
The “Metabolic” Domains in the 
Complement C3 Component
C3 activation is at the very heart of complement function and 
likely represents the origin of the complement system (111). C3 
opsonic activity is mediated by an intrachain thioester bond that, 
when activated via proteolytic cleavage of C3a or activation of C3 
via hydrolysis (10), attaches C3b/C3H2O covalently to surfaces 
and promotes target opsonization and further complement 
activation (112). C3 belongs to the TEP family that is divided 
into two subfamilies: the alpha-2-macroglobulin (A2M) and the 
C3 subfamilies. In humans, the C3 subfamily comprises C3, C4, 
and C5, and the A2M family consists of A2M, CD109, pregnancy 
zone protein (PZP), the PZP-like A2M domain-containing 8 
(CPAMD8) protein, and A2M-like protein 1 (A2ML1) (102, 113–
115). The A2M subfamily members are characterized by a specific 
“protease bait domain” and the C3 subfamily members contain 
FiGURe 5 | Schematic depicting appearance of the “original” complement components during evolution. (A) Simplified phylogenic tree of species with 
emphasis on families and species important during evolution of the complement system (see text). (B) Cartoon depicting the appearance of complement(s) C3/C4/
C5, factor B (FB), and earliest members of the MASP families during evolution. Color coding in the “title arrow” corresponds to specific key species in the 
phylogenetic tree under (A). Note that the appearance of fully functional TTC/MAC components and complement receptors and regulators are not depicted in this 
schematic.
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an anaphylatoxin (ANA) and N-terminal region-like [NTR; also 
known as C-terminal of C3, C4, and C5 (C345C)] domain. A2M 
is secreted by the liver, present in high amounts in serum, and 
functions as an anti-protease as it can trap and inactive a broad 
range of proteases by covalently attaching to target proteases via 
its thioester (116). While the exact evolutionary origin of TEP 
proteins remains to be clarified, A2M-like proteins were recently 
identified in the periplasm of pathogenically invasive bacteria 
that colonize higher eukaryotes (117).
In (higher) vertebrates, the C3 structure is highly conserved 
with C3, C4, and C5 all containing A2M, isopren C2-like 
domains, and NTR domains (Figure  6A). Interestingly, our 
analysis of protein domains particularly in the evolutionary 
older C3 molecules revealed that they often contained additional 
domains with homology to enzymes and proteins involved in 
metabolism and/or protein turnover (Figure 6B). “Modern” C3 
contains an isopren C3-like domain that is commonly found in 
squalene cyclases and 2,3-oxidosqualene cyclases superfamilies 
(118). These membrane proteins catalyze a cationic cyclization 
cascade converting linear triterpenes to fused ring compounds 
and are thought to be evolutionary precursors to sterol cyclases, 
which are key enzymes in cholesterol metabolism (119). Similarly, 
the NTR-like domain within C3, C4, and C5 is found in proteins 
regulating directional axonal growth and cell migration during 
neural development (120, 121) and in tissue inhibitors of metal-
loproteinases, which are instrumental in regulating extracellular 
matrix turnover (122).
Domains found in “older” C3 forms that have been lost in C3 
from higher vertebrates (Figure 6B) include the crotonase (Crot) 
domain, which is characteristic of members of the crotonase/
Enoyl-Coenzyme A (CoA) hydratase superfamily. This super-
family represents a diverse range of enzymes including enoyl-
CoA hydratase and dienoyl-CoA isomerase, which catalize the 
β-oxidation of fatty acids (123, 124). The 7-lung-transmembrane 
domain has homology with GPCRs found in desmosponges, 
invertebrates, and amoebozoa species (125, 126). The only human 
protein containing this domain is GPR107. GPR107 localizes to 
the Golgi and is essential for intracellular vesicular transport 
(127) and proglucagon mRNA synthesis in pancreatic α-cells 
(128). The FNR domain within C3 from Neognathae can be traced 
back to proteins found already in ancient anaerobic bacteria 
and cyanobacteria. This domain is characteristic of ferredoxin 
NADP(H) reductase (FNR) superfamily members (129) that 
function as cofactors for flavin adenine dinucleotides, which 
bind and reduce nicotinamide adenine dinucleotide. FNR was 
initially identified as catalysator of electron transfer from reduced 
iron–sulfur protein ferredoxin to NADP+, which is the final step 
in the electron transport (ET) mechanism of the Photosystem I 
(130, 131). In humans, FNR is found in mitochondria where it 
serves as first ET protein in the P450 complex and it thus involved 
in sterol, cholesterol, and steroid metabolism (132, 133).
The presence of these metabolism-related domains in 
evolutionary older C3/C4/C5 molecules suggests indeed that 
the complosome–metabolism relationship goes far back and 
may have contributed to regulation of other key pathways that 
evolved during the transition from single-cell ancestors to mul-
ticellular animals such as those regulating tissue specialization 
and recognition of self. Thus, it may be worthy to now assess 
(immune) cell-generated intracellular C3 for novel functions that 
could possibly include unexpected direct metabolic/enzymatic 
activities. However, several of these “metabolic” domains in C3 
have been lost during the molecular evolution of this family in 
higher vertebrates while some have been retained. The reasons are 
unclear, but this could have been driven by the further specializa-
tion of C3/C4/C5 into a secreted danger sensing system and the 
concurrent divergent development of an increasingly complex 
and “dedicated” metabolic machinery. Although the enzymatic C3 
domains could give clues to additional novel functions for comple-
ment in metabolism, one should be conscious of these divergence 
events when studying the role of complement in cell metabolism 
using different species. Furthermore, several domains within C3 
that thought to serve simple structural purpose such as the C1r/
C1s, Uegf, Bmp1 (CUB) domain may actually also contribute 
to novel C3 activities that could involve regulation of metabolic 
enzymes: the CUB domain in other protein families is involved 
in oligomerization and recognition of binding partners. Aligning 
with the idea that the interaction of C3/C3b with other proteins 
(aside from activation fragment receptors) may go beyond mere 
target opsonization, we have observed that C3b indeed associates 
with mTOR and 5′ AMP-activated protein kinase AMPK within 
cells (unpublished data); however, the functional consequence of 
this interaction remains to be defined.
Complement and Mitochondria
While C3 in higher vertebrates may have lost several metabolic 
domains, it seems that another “younger” complement compo-
nent that evolved during transition from jawless to jawed verte-
brates, C1q, did develop a strong connection to cell metabolism 
and particularly with mitochondrial function. C1q consists of 
globular heads that recognize antigen-bound IgM and IgG and 
a collagen-like stalk region [see Figure  1 and Ref. (134)] and 
its basic structure is therefore very similar to that of mannose-
binding lectin (MBL), one of the initiating molecules of the lectin 
pathway (105). Apart from its well-defined serum-active func-
tions in complement classical pathway activation and the tagging 
and clearance induction of apoptotic cells (2), C1q was shown 
to be present within cells (135, 136) and one of the receptors for 
C1q, globular head C1q receptor (gC1qR), is located on/in mito-
chondria (137). Aligning with these data, C1q has been shown 
to mediate mitochondrial ROS production by cortical neurons 
in neonatal hypoxic-ischemic brain injury (135). Furthermore, 
at least 15 hybrid molecules between C1q and the key growth 
factor tumor necrosis factor (TNF) have been described (138) 
with most members of this C1q–TNF superfamily displaying 
metabolic functions. For example, C1q–TNF-related proteins 
2, 5, 6, 9, and 13 all increase fatty acid oxidation via activation 
of AMPK (139) and/or acetyl coenzyme A carboxylase (140) in 
several cell types. In addition, C1q–TNF-related proteins 1, 3, 
and 9 also activate MAPKs and AKT, which are key upstream 
initiators of mTOR activity [reviewed extensively in Ref. (141) 
and see Section “Introduction” above]. C1q–TNF-related protein 
3 also drives OXPHOS-supported protein expression and mito-
chondrial ROS production within smooth muscle cells (142), 
while exogenous addition of this protein blocked apoptosis of 
FiGURe 6 | Continued
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“Metabolic domains” in modern and ancient C3 forms. The basic domain structure of C3 is not only conserved among species but also contains several 
domains that have high homology to proteins with key metabolic functions (see text for further details). (A) Compared to C3 found in “modern” higher vertebrates, 
C3 forms in (B) more ancient and basic organisms contained additional domains involved in core metabolic processes. These “lost metabolic” domains are shown in 
bright red (please see text for details). A, anaphylatoxin-like domain; A2M-N, domain with high homology to the N-terminal part of the A2M (alpha-2-macroglobulin) 
domain; different colors in the A2M domains indicate protein sequence differences among the A2M domains within one C3 form.
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mesenchymal stem cells due to activation of the PI3K–AKT–
mTOR axis (143). Importantly, using C1q–TNF-related protein 
3 siRNA knockdown technique, the authors of this latter study 
demonstrated that intracellular and/or autocrine C1q synthesis 
rather than systemic production was important for its function 
(142). Finally, and similar to C1q, intracellular C1q–TNF-related 
protein 3 can bind directly to mitochondrial protein cyclophilin 
D and protects cells against oxidative stress (144). The existence 
of these C1q–TNF hybrid proteins is intriguing as TNF itself is 
a master regulator of a broad range of metabolic pathways in 
almost all cell subpopulations (145). As most studies on these 
chimeric molecules have so far focused on the C1q portion, it 
will be important to also define the TNF domain contributions 
and to possibly dissect the exact “combined” functions of C1q-
TNF hybrid proteins versus those of “standalone” TNF and C1q 
in mitochondria. Furthermore, patients with homozygous C1q 
deficiency suffer mostly from SLE and glomerulonephritis, and 
both diseases have been connected with an increase in deposition 
of apoptotic cell bodies in tissues due to reduced C1q-mediated 
clearance of dying cells (146, 147). Given the emerging novel role 
for intracellular C1q in cell metabolism, an investigation into 
whether C1q defects could provide additional pathophysiologi-
cal mechanisms contributing to these disease settings may be 
warranted.
Mitochondria are thought to originate from ancient 
α-protobacteria, which invaded archaea-type hosts, and that 
resulted in their symbiotic relationship, which ultimately led 
to the emergence of eukaryotic cells approximately 1.5 billion 
years ago (148). This acceptance of the probacteria by their 
early hosts could only occur if probacteria would fail to induce a 
proinflammatory response—and indeed, isolated mitochondria 
do not evoke significant complement activation (149). “Modern 
day” bacteria and unicellular eukaryotic organisms, on the other 
hand, face the opsonic and lytic complement system in serum and 
have therefore evolved numerous evasion strategies (150–152). 
For example, Borrelia burgdorferi expresses a CD59-analog that 
blocks formation of the TCC/MAC pore and protects them from 
lysis (152), and viruses have developed numerous evasion strate-
gies based on the acquisition of complement regulators such as 
vaccinia complement control protein and monkey pox inhibitor 
of complement enzymes into their genome [reviewed in Ref. (11, 
152)]. Critically, while evolutionary pressure on multicellular 
eukaryotes resulted in larger and more complex genomes with an 
increased pool of specialized proteins (153), in bacteria, this pres-
sure led to a streamlining of their respective genomes with loss of 
non-essential genes and emergence of “multitasking” proteins that 
served several key functions in parallel (154). This is, for example, 
exemplified in Candida albicans, which has a CR3 analog termed 
Hgt1p that binds to FH and protects the yeast from complement 
lysis but that also “doubles” as a high-affinity glucose transporter 
(155). It is therefore feasible that other complement analog eva-
sion molecules expressed by bacteria, viruses, and unicellular 
eukaryotes might also have additional simultaneous functions in 
microbial physiology. Conversely, while the virus-induced and 
C3-dependent activation of the mitochondrial antiviral signal-
ing protein (MAVS) in human epithelial cells induces protective 
IFN type I responses during infection (156), we can envision 
that intracellular C3 activation fragments not only contribute to 
defense against viruses but possibly also to normal mitochon-
drial function in resting and activated cells. In this regard, it is 
noteworthy that the only cell type in the human body lacking 
mitochondria are erythrocytes (157) and that erythrocytes are 
also the only cells devoid of CD46 expression (158). It is generally 
speculated that the “loss” of CD46 expression by red blood cells is 
a protective measure against fast spread of measles virus [which 
uses CD46 as cell entry receptor (6)]. However, there could be an 
alternative explanation pointing to a novel role for CD46 in cell 
metabolism: intriguingly, avian erythrocytes contain functional 
mitochondria (159) and their red blood cells do express the CD46 
analog molecules CREG and CREM (160). Thus, it would be of 
interest to assess in the future whether intracellular CD46 (which 
we have observed in several cells)—possibly via engagement 
through intracellularly generated C3b—may have a yet undiscov-
ered function in mitochondrial biogenesis and/or activity.
Although we are now only slowly beginning to understand 
and appreciate the close connection between complement, the 
complosome, and metabolism, its impact could be enormous. 
This system not only plays a central role in metabolic diseases 
(6), it is also entirely thinkable now that complement may directly 
impact on a process that has been a fundamental interest in 
human philosophy and medicine alike since centuries—aging. 
Restriction of caloric intake has long been recognized to extend 
the life span in several animal species, including humans. The 
underlying mechanisms are not entirely clear, but seem to include 
a combined effect on reduced cell turnover and autophagy, 
altered redox balance, and insulin responsiveness (161, 162). 
Complement is at the nexus of these processes, and several topi-
cal studies indeed suggest direct links between complement and 
aging: C3a downregulates proteasome activity (which is essential 
to normal protein turnover) in human pigment epithelial cells 
from older individuals, thereby connecting the complement 
system with intracellular protein longevity (163); C1q levels 
increase with age and C1q-mediated activation of canonical wnt 
signaling—which has been implicated in mammalian aging—
promotes age-associated decline in tissue regeneration in mice 
(164), and C3aR and C5aR activation may regulate telomerase 
activity and preservation of telomer length in cardiac-resident 
stem cells (165). Against this background, it will be exciting to 
now (re)explore the full range of the “powers of this unexpected 
force from within the cell.”
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FUTURe PeRSPeCTiveS
The unanticipated discovery of the complosome and its key 
contributions to basic metabolic processes of the cell opened up 
exciting new avenues to explore novel complement activities, but 
it also left us with far more questions than answers. From the 
few insights we have gained so far, it is clear that the location 
of complement activation (extracellular versus intracellular) 
dictates its function. However, also the functional outcome of 
complement activation within cells is likely strongly dependent 
on the subcellular compartment in which it takes place and 
where the receptors reside that intracellulary sense and respond 
to complement activation. Thus, among the many pressing ques-
tions that we now raise are, for example: is the composition of the 
complosome universal or cell specific? Which exact cellular sub-
compartments contain complement components and receptors 
and regulators for activation fragments? How is the complosome 
regulated? How does the complosome intersect with extracellular 
complement? Finding the answers to these queries will not only 
enhance our understanding of these rather unexpected facets of 
this ancient system but also create new opportunities to thera-
peutically target it.
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